Abstract
Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.
| Original language | English |
|---|---|
| Pages (from-to) | 549-553 |
| Number of pages | 5 |
| Journal | Thrombosis and Haemostasis |
| Volume | 83 |
| Issue number | 4 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Coronary artery disease
- Fibrate
- Fibrinogen
- Statin
ASJC Scopus subject areas
- Hematology
Cite this
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). / Cortellaro, Michele; Cofrancesco, E.; Boschetti, C.; Cortellaro, F.; Mancini, M.; Mariani, M.; Paoletti, R.
In: Thrombosis and Haemostasis, Vol. 83, No. 4, 2000, p. 549-553.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study)
AU - Cortellaro, Michele
AU - Cofrancesco, E.
AU - Boschetti, C.
AU - Cortellaro, F.
AU - Mancini, M.
AU - Mariani, M.
AU - Paoletti, R.
PY - 2000
Y1 - 2000
N2 - Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.
AB - Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.
KW - Coronary artery disease
KW - Fibrate
KW - Fibrinogen
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=0034035848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034035848&partnerID=8YFLogxK
M3 - Article
C2 - 10780315
AN - SCOPUS:0034035848
VL - 83
SP - 549
EP - 553
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
SN - 0340-6245
IS - 4
ER -